+83%

est. 2Y upside i

HealthcareSeries B

Numan is on a mission to make people healthier. We provide healthcare as people need it, and treat common health conditions with personalised plans that alleviate symptoms and fix root causes. We offer integrated care - including diagnostics, medication & supplements, 1-1 clinical care, and digital programs - in one digital platform, to help patients take control of their health.

Rank

#32

Sector

Healthtech

Est. Liquidity

~4Y

Data Quality

Data: Medium

Numan presents a strong upside opportunity for a job seeker, driven by its impressive 143% YoY revenue growth to $90M (projected $225M in 2025) and current profitability.

Last updated: March 10, 2026

Bull (35%)+300%

Numan capitalizes on the booming GLP-1 market, successfully expands into women's health, and leverages its AI assistant to drive patient engagement and retention. Revenue exceeds $900M by 2027, justifying a $4.8B+ valuation at a 5x+ revenue multiple, reaching the Series B upside cap.

Base (35%)+280%

Numan maintains strong growth in obesity management and men's health, with moderate success in women's health. Revenue reaches ~$765M by 2027, leading to a $4.59B valuation at a 6x revenue multiple, reflecting continued market penetration and profitability.

Bear (30%)-50%

Increased competition from Hims & Hers and traditional pharmacies, coupled with potential regulatory headwinds and pricing pressure in the GLP-1 market, significantly slows Numan's growth. Revenue struggles to reach $400M by 2027, resulting in a down round or acquisition at $600M, wiping out a significant portion of common stock value.

Est. time to liquidity~4.0 years

Preference Stack Risk

moderate

Investors hold $150M in liquidation preferences, which represents 12.5% of the estimated $1.2B current valuation.

Dilution Risk

moderate

As a Series B company, Numan will likely undergo at least one to two more significant funding rounds, leading to further dilution for common shareholders.

Secondary Liquidity

none

There is no indication of an active secondary market or tender offers for Numan's shares at this stage.

Questions to Ask at the Interview

Strategic questions based on Numan's data — designed to show you've done your homework.

  • 1

    “Given the significant revenue contribution from GLP-1s, how is Numan strategizing to mitigate risks associated with potential market saturation, new drug competition, or regulatory changes in this segment, especially with competitors like Hims & Hers actively expanding?”

  • 2

    “With the projected 150% growth for 2025 and expansion into women's health, what are the key operational and clinical challenges Numan anticipates, and how will the recent $60M funding specifically support scaling these new initiatives while maintaining profitability?”

  • 3

    “Considering Numan's Series B extension and total funding of $150M, what is the company's long-term vision for a liquidity event (IPO or acquisition), and what milestones are critical to achieving that timeline for employees holding equity?”

Community

Valuation Sentiment

Our model estimates +83% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.